RLMD
NASDAQ HealthcareRelmada Therapeutics, Inc. - Common Stock
Biotechnology
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
�� 市场数据
| 价格 | $7.48 |
|---|---|
| 成交量 | 2,372,220 |
| 市值 | 784.58M |
| RSI（14日） | 66.2 |
| 200日均线 | $3.25 |
| 50日均线 | $5.66 |
| 52周最高 | $7.94 |
| 52周最低 | $0.27 |
| Forward P/E | -18.24 |
| Price / Book | 6.34 |
🎯 投资策略评分
RLMD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (34/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RLMD in your text
粘贴任何文章、记录或帖子 — 工具将提取 RLMD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.